Trials / Completed
CompletedNCT02681718
Controlling Hyperglycemia Among Minority Population
Controlling Hyperglycemia Among Minority Population (CHAMP): A Randomized Controlled Trial of Two Diabetes Interventions for Underserved Communities
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- Sinai Health System · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the efficacy of three approaches in diabetes management: (1) community health worker (CHW) education; (2) text messaging; and (3) usual hospital-based care. The goal is to determine the most cost-effective method of diabetes management among an economically-disadvantaged, minority population.
Detailed description
The CHAMP study will test the efficacy of two interventions designed to decrease uncontrolled hyperglycemia (defined as Hemoglobin-A1C (A1C) at or above 9%) among adults with diabetes. Patients from a safety-net hospital will be randomized into three groups: 1) a control group, 2) an intervention providing diabetes self-care text messages, or 3) an intervention using community health workers to provide diabetes education and linkage to care. Secondary objectives include increasing diabetes knowledge, improving diabetes self-management, and increasing use of primary care (i.e., make one visit to the physician in 6 months) among the intervention participants. A cost-effectiveness analysis will determine the most appropriate way to reduce the burden of uncontrolled diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Community health worker education | Diabetes self-management education by community health workers |
| BEHAVIORAL | Cell phone text messaging | Diabetes self-management education through cell phone text messaging |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2016-02-12
- Last updated
- 2018-01-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02681718. Inclusion in this directory is not an endorsement.